Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many cases were asymptomatic.
Published: November 22, 2021 at 05:00PM
from NYT Health https://ift.tt/30M07J8